甲状腺切除术特异性结局的医院间变异及其与风险调整和医院绩效的关联
结果显示低钙血症和喉返神经损伤的医院绩效存在差异,而血肿无差异;将甲状腺切除术特异性变量纳入风险调整后医院排名基本不变。表现最佳医院更少测量术后甲状旁腺激素,更常处方钙剂/维生素D,且更常用能量器械和术中神经监测。
要点
- 低钙血症和喉返神经损伤可作为甲状腺切除术特异性医院质量指标,血肿则不能。
- 将甲状腺切除术特异性数据纳入风险调整对医院绩效排名影响不大。
- 表现最佳医院更常处方口服钙剂/维生素D,更少测量术后甲状旁腺激素。
核心结论
- 术后低钙血症和喉返神经损伤可能作为甲状腺切除术特异性国家医院质量改进指标,而血肿不适合。
主要发现
- 临床严重低钙血症发生于450例(总体3.3%,部分切除0.6%,次全或全切除4.7%)。
- 喉返神经损伤发生于755例(总体5.7%,部分切除4.2%,次全或全切除6.6%)。
- 血肿发生于175例(1.3%)。
- 低钙血症和喉返神经损伤的医院绩效存在变异,血肿无变异。
- 将甲状腺切除术特异性数据纳入风险调整后,医院绩效排名基本不受影响。
关键数值与推荐
- 表现最佳医院与最差医院相比,术后甲状旁腺激素测量率更低(593例[19.9%] vs 457例[31.7%],P < .001)。
- 表现最佳医院与最差医院相比,口服钙剂、维生素D或两者处方的比例更高(2281例[76.6%] vs 962例[66.8%],P < .001)。
- 按喉返神经损伤分析,表现最佳医院与最差医院相比,能量器械使用更普遍(1517例[69.1%] vs 507例[55.2%],P < .001)。
- 按喉返神经损伤分析,表现最佳医院与最差医院相比,术中神经监测使用更普遍(1223例[55.7%] vs 346例[37.7%],P < .001)。
临床怎么用
- 可考虑将术后低钙血症和喉返神经损伤作为甲状腺切除术的医院质量监测指标。
- 关注术后甲状旁腺激素测量和钙剂/维生素D处方等围术期管理流程,可能有助于改善结局。
- 能量器械和术中神经监测的使用与喉返神经损伤相关绩效有关,但需结合具体情况评估。
局限性
- 由于排除缺失甲状腺切除术特异性结局的手术,各结局分析的手术和医院数量不同。
- 研究为回顾性设计,可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Current surgical quality metrics might be insufficient to fully judge the quality of certain operations because they are not procedure specific. Hypocalcemia, recurrent laryngeal nerve (RLN) injury, and hematoma are considered to be the most relevant outcomes to measure after thyroidectomy. Whether these outcomes can be used as hospital quality metrics is unknown. OBJECTIVES: To evaluate whether thyroidectomy-specific outcomes vary among hospitals, whether the addition of thyroidectomy-specific variables affects risk adjustment, and whether differences in hospital performance are associated with thyroidectomy-specific care processes. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, patients undergoing thyroidectomies from January 1, 2013, through December 31, 2015, at hospitals participating in the American College of Surgeons' National Surgical Quality Improvement Program were studied. EXPOSURE: Thyroidectomy-related care. MAIN OUTCOMES AND MEASURES: Clinically severe hypocalcemia, RLN injury, and clinically significant hematoma within 30 days of thyroid surgery and hospital-level performance variation, change in risk adjustment, and association with processes. RESULTS: Overall, 14 540 patients (mean [SD] age, 52.1 [15.0] years; 11 499 [79.1%] female) underwent operations at 98 hospitals. Because operations missing thyroidectomy-specific outcomes were excluded, the numbers of operations and hospitals analyzed differed by outcome. Of 14 540 operations included, clinically severe hypocalcemia occurred in 450 patients (3.3% overall, 0.6% after partial, and 4.7% after subtotal or total thyroidectomy), RLN injury in 755 patients (5.7% overall, 4.2% after partial, and 6.6% after subtotal or total thyroidectomy), and hematoma in 175 patients (1.3%). Hospital performance varied for hypocalcemia and RLN injury but not for hematoma. Hospital performance rankings were largely unaffected by the inclusion of thyroidectomy-specific data in risk adjustment. With regard to processes, patients undergoing thyroidectomies at the best-performing vs worst-performing hospitals less frequently had their postoperative parathyroid hormone level measured (593 [19.9%] vs 457 [31.7%], P < .001) and more often were prescribed oral calcium, vitamin D, or both (2281 [76.6%] vs 962 [66.8%], P < .001). When profiled by RLN injury, use of energy devices (1517 [69.1%] vs 507 [55.2%], P < .001) and intraoperative nerve monitoring (1223 [55.7%] vs 346 [37.7%], P < .001) were more prevalent at the best- compared with the worst-performing hospitals. CONCLUSIONS AND RELEVANCE: Postoperative hypocalcemia and RLN injury, but not hematoma, potentially could be used as thyroidectomy-specific national hospital quality improvement metrics. Strategies aimed at reducing these complications after thyroidectomy may improve the care of these patients.
引用
- Liu JB, Sosa JA, Grogan RH, et al. Variation of Thyroidectomy-Specific Outcomes Among Hospitals and Their Association With Risk Adjustment and Hospital Performance. JAMA Surg. 2018. PMID: 29188293. doi:10.1001/jamasurg.2017.4593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。